Last reviewed · How we verify
A Prospective Randomized Controlled Trial Evaluating the Safety and Efficacy of Patient Blood Management Program in Patients With Gynecologic Cancer
To demonstrate the safety and effectiveness of a patient blood management program in gynecological cancer patients
Details
| Lead sponsor | Asan Medical Center |
|---|---|
| Phase | NA |
| Status | UNKNOWN |
| Enrolment | 334 |
| Start date | 2023-02 |
| Completion | 2025-12 |
Conditions
- Gynecologic Cancer
Interventions
- Ferric Carboxymaltose 50Mg/Ml Inj 20Ml
- RBC
Primary outcomes
- transfusion rate — within 3 weeks after surgery
Transfusion rate within 3 weeks after surgery, radiation and chemotherapy treatment
Countries
South Korea